Roswell Park study: Targeting HSP60-ClpP axis may improve outcomes in prostate cancer

Pfizer announced positive topline results from the phase III TALAPRO-3 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway inhibitor, in people with homologous recombination repair gene-mutated metastatic castration-sensitive prostate cancer, also known as metastatic hormone-sensitive prostate cancer.

A team of researchers engineered a new class of “turbocharged” T cells that may be stronger, longer-lasting, and more precise at killing prostate cancer cells. The approach represents a step toward developing safer, more effective T-cell therapies for prostate cancer and could potentially be adapted to treat a wide range of other tumors.

Androgen receptor alterations consistently emerged in serial liquid biopsies researchers used to track how metastatic prostate cancer evolves under treatment pressure. These alterations were linked to poorer outcomes across therapies, according to a multi-center collaboration of investigators from Sylvester, UC San Diego, Moores Cancer Center, the University of California, San Francisco, Scripps Research Institute, and Guardant Health.